ReviewDiagnostics (Basel, Switzerland)2022
The Role and Potential of
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Comparison of [European radiology · 2026Pooled it
- Insights into pet-based radiogenomics in oncology: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Review
- Prognostic value of a combined model integrating clinical and PET radiomics parameters in metastatic melanoma: A dual-center retrospective study.Annals of nuclear medicine · 2026Article
- TREM1-PET imaging maps whole-body innate immune responses in a mouse model of metastatic melanoma.Scientific reports · 2026Article
- Article
- Radiopharmaceuticals in Malignant Melanoma: A Comprehensive Review of Diagnostic, Therapeutic, and Immune-Related Applications by PET/CT, SPECT/CT, and PET/MRI.Diagnostics (Basel, Switzerland) · 2025Review
- The untapped potential of dosomics for theranostics: shaping the future of personalized medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- Synthetic imaging for research and education in nuclear medicine: Who's afraid of the black box?European journal of nuclear medicine and molecular imaging · 2025Article
- Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors.Scientific reports · 2025Article
- Assessing the Potential Usefulness of FDG LAFOV-PET for Oncological Staging: An Evaluation of Lesion Number and Uptake.Cancers · 2025Article
- Association of [Diagnostics (Basel, Switzerland) · 2025Article
- [18F]-FDG PET-CT in Malignant Melanoma.Diagnostics (Basel, Switzerland) · 2025Article
- A Rare Case of Xeroderma Pigmentosum: Nivolumab Treatment for Three Cutaneous Malignancies with Clinical and Metabolic Imaging Correlation.Diagnostics (Basel, Switzerland) · 2025Article
- Spontaneous Necrosis of a High-Risk Bladder Tumor Under Immunotherapy for Concurrent Malignant Melanoma: Role of BRAF Mutations and PD-L1 Expression.Biomedicines · 2025Article
- Article
- This union must happen: Radiomics and LAFOV PET/CT as the power couple of nuclear medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- SmartSkin-XAI: An Interpretable Deep Learning Approach for Enhanced Skin Cancer Diagnosis in Smart Healthcare.Diagnostics (Basel, Switzerland) · 2024Article
- It Looks Like a Zebra but Is Not: [Diagnostics (Basel, Switzerland) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel therapeutic approaches, consisting of immune check-point inhibitors (ICIs) and molecularly targeted therapy, have thoroughly changed the clinical management of malignant melanoma (MM), the most frequent and deadly skin cancer. Since only 30-40% of MM patients respond to ICIs, imaging biomarkers suitable for the pre-therapeutic stratification and response assessment are warmly welcome. In this scenario, positron emission computed tomography (PET/CT) with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.